Aspect Biosystems – Transforming Regenerative Medicine
A trailblazer in regenerative medicine, Aspect Biosystems captured Pangaea Ventures’ interest right from the start. Having followed this impressive company for a long time, we made a decision to invest in 2017 following a pivotal conversation with Tamer Mohamed, Aspect’s CEO, during a two-hour airport shuttle ride. They were ready for the next stage of growth, and we were equally prepared and ready to support them.
Chronic diseases, such as diabetes and liver disease are on the rise globally, placing a growing strain on healthcare systems. Current treatment options are often limited, invasive, and can come with significant side effects. More importantly, they frequently fail to offer a long-term cure, which leaves millions of patients managing symptoms rather than addressing root causes. Traditional methods of tissue regeneration struggle to keep pace with patient needs, and organ transplants remain challenging due to donor shortages and compatibility issues.
Aspect Biosystems, headquartered in Vancouver, is on a mission to solve these challenges by developing bioprinted tissue therapeutics. Through its proprietary bioprinting technology, Aspect creates functional human tissues with unprecedented precision and control. These 3D-printed tissues can restore a diseased state without the constraints of traditional organ transplantation.
Aspect’s patented microfluidic 3D bioprinting technology is the backbone of its tissue therapeutics platform. Unlike traditional bioprinting methods, which may struggle with cell placement and tissue viability, Aspect’s approach combines microfluidics with 3D printing to maintain cell function and tissue stability. This allows the company to create highly functional and scalable tissues tailored for therapeutic use. In addition to its applications in diabetes and liver disease, Aspect’s technology has potential applications across a wide range of diseases, positioning it as a leader in next-generation medical solutions.
Pangaea Ventures saw a unique opportunity with Aspect Biosystems to create a meaningful impact in the healthcare sector. Their technology aligns perfectly with our mission to foster breakthrough technologies in hard tech sectors that can significantly improve lives and reshape industries. Says Andrew Haughian, General Partner at Pangaea Ventures, “Aspect has multiple products in its pipeline that show promising data equivalent to the most transformative new therapeutics. But the biology they are using is generally well understood, so the technical risk profile is more around engineering than science. This has allowed them to build a rich product pipeline around metabolic and endocrine disease in just a few short years.”
With its promising advancements in bioprinting technology, Aspect Biosystems is well-positioned to transform the field of regenerative medicine. We are proud to support Aspect in its journey to develop life-saving tissue therapeutics and deliver real, lasting change to patients around the world. As Aspect continues to grow, we are excited to see how they push the boundaries of medical science and redefine what’s possible in human health.
